Integrated proteogenomic characterization of glioblastoma evolution
- Authors
- Kim, Kyung-Hee; Migliozzi, Simona; Koo, Harim; Hong, Jun-Hee; Park, Seung Min; Kim, Sooheon; Kwon, Hyung Joon; Ha, Seokjun; Garofano, Luciano; Oh, Young Taek; D'Angelo, Fulvio; Kim, Chan Il; Kim, Seongsoo; Lee, Ji Yoon; Kim, Jiwon; Hong, Jisoo; Jang, Eun-Hae; Mathon, Bertrand; Di Stefano, Anna-Luisa; Bielle, Franck; Laurenge, Alice; Nesvizhskii, Alexey I.; Hur, Eun-Mi; Yin, Jinlong; Shi, Bingyang; Kim, Youngwook; Moon, Kyung-Sub; Kwon, Jeong Taik; Lee, Shin Heon; Lee, Seung Hoon; Gwak, Ho Shin; Lasorella, Anna; Yoo, Heon; Sanson, Marc; Sa, Jason K.; Park, Chul-Kee; Nam, Do-Hyun; Iavarone, Antonio; Park, Jong Bae
- Issue Date
- 11-Mar-2024
- Publisher
- Cell Press
- Keywords
- BRAF; longitudinal glioblastoma; neuronal; proteogenomics; recurrence; synapse
- Citation
- Cancer Cell, v.42, no.3, pp 358 - 377.e8
- Indexed
- SCIE
SCOPUS
- Journal Title
- Cancer Cell
- Volume
- 42
- Number
- 3
- Start Page
- 358
- End Page
- 377.e8
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/110154
- DOI
- 10.1016/j.ccell.2023.12.015
- ISSN
- 1535-6108
1878-3686
- Abstract
- The evolutionary trajectory of glioblastoma (GBM) is a multifaceted biological process that extends beyond genetic alterations alone. Here, we perform an integrative proteogenomic analysis of 123 longitudinal glioblastoma pairs and identify a highly proliferative cellular state at diagnosis and replacement by activation of neuronal transition and synaptogenic pathways in recurrent tumors. Proteomic and phosphoproteomic analyses reveal that the molecular transition to neuronal state at recurrence is marked by post-translational activation of the wingless-related integration site (WNT)/ planar cell polarity (PCP) signaling pathway and BRAF protein kinase. Consistently, multi-omic analysis of patient-derived xenograft (PDX) models mirror similar patterns of evolutionary trajectory. Inhibition of B-raf proto-oncogene (BRAF) kinase impairs both neuronal transition and migration capability of recurrent tumor cells, phenotypic hallmarks of post-therapy progression. Combinatorial treatment of temozolomide (TMZ) with BRAF inhibitor, vemurafenib, significantly extends the survival of PDX models. This study provides comprehensive insights into the biological mechanisms of glioblastoma evolution and treatment resistance, highlighting promising therapeutic strategies for clinical intervention. © 2023 Elsevier Inc.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/110154)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.